Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.170
-0.060 (-4.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
221,618
Open
1.230
Bid (Size)
1.180 (5)
Ask (Size)
1.210 (10)
Prev. Close
1.230
Today's Range
1.160 - 1.230
52wk Range
0.9501 - 31.74
Shares Outstanding
171,350,166
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award
August 20, 2024
Via
ACCESSWIRE
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
August 19, 2024
Via
ACCESSWIRE
Performance
YTD
-87.10%
-87.10%
1 Month
-8.59%
-8.59%
3 Month
-70.97%
-70.97%
6 Month
-67.50%
-67.50%
1 Year
-95.19%
-95.19%
More News
Read More
JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q2 2024
August 13, 2024
Via
InvestorPlace
Why Jaguar Health (JAGX) Stock Is Down 15%
August 13, 2024
Via
Benzinga
Jaguar Health Reports Second Quarter 2024 Financial Results
August 13, 2024
Via
ACCESSWIRE
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
August 12, 2024
Via
ACCESSWIRE
Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
July 31, 2024
Via
ACCESSWIRE
Why Jaguar Health Stock Is Crashing
July 23, 2024
Via
Benzinga
Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
June 26, 2024
Via
ACCESSWIRE
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
June 21, 2024
Via
ACCESSWIRE
Jaguar Health Issues Shareholder Letter: Company to Explore Approval Pathway for Crofelemer in Breast and Lung Cancer Based on Phase 3 Results - Investor Webcast August 13th Will Review Q2 Earnings and Further Review OnTarget Trial’s Clinically Meaningful
August 05, 2024
Via
ACCESSWIRE
Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
August 02, 2024
Via
ACCESSWIRE
Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting
August 01, 2024
Via
ACCESSWIRE
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
July 23, 2024
Via
Benzinga
Why Is Azitra (AZTR) Stock Up 315% Today?
July 23, 2024
Via
InvestorPlace
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 23, 2024
Via
Benzinga
Spot Ethereum ETFs: 9 Tickers to Watch as New Funds Start Trading
July 23, 2024
Via
InvestorPlace
Topics
ETFs
Why Is Serve Robotics (SERV) Stock Down Today?
July 23, 2024
Via
InvestorPlace
Why Is Jaguar Health (JAGX) Stock Down 55% Today?
July 23, 2024
Via
InvestorPlace
Crude Oil Down 2%; GE Aerospace Earnings Top Views
July 23, 2024
Via
Benzinga
Exposures
Fossil Fuels
US Stocks Edge Higher; General Motors Posts Upbeat Earnings
July 23, 2024
Via
Benzinga
Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer
July 23, 2024
Via
ACCESSWIRE
Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning
July 18, 2024
Via
ACCESSWIRE
Issuance of New European & Australian Patents Bolster IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDDs)
July 08, 2024
Via
ACCESSWIRE
Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
June 12, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.